Multiple Sclerosis
Multiple sclerosis was long dismissed as a disease of the Global North. That assumption is now collapsing. Recent epidemiological work in Sudan, Kenya, South Africa, and Zambia indicates that MS prevalence among Black Africans is not low — it is unmeasured, underdiagnosed, and rising. With Africa holding the world's lowest density of MRI scanners and neurologists, the vast majority of Africans living with MS will spend years without a confirmed diagnosis, while their counterparts in the diaspora — particularly Black Americans — bear measurably more severe disease courses than non-Hispanic White patients.
Statistics on the African and Diaspora MS Burden
| Indicator | Statistic | Source |
|---|---|---|
| MS prevalence in Africa (median) | 0.3 per 100,000 | MSIF Atlas of MS, 3rd Edition (2020) |
| MS prevalence in Europe (median) | 80 per 100,000 | MSIF Atlas of MS, 3rd Edition (2020) |
| African countries with no MS data | 25 nations | MSIF Atlas of MS, 3rd Edition (2020) |
| MRI scanners in Africa | 0.7 per million people | Murray et al., 2025 |
| Neurologist density in Africa | 0.03 per 100,000 | Adekanmbi et al., 2024 (IJMSC) |
| Median MS diagnostic delay in Zambia | 11.4 months (IQR 4–35.5) | Sahu et al., 2025 (MS Journal) |
| Global rise in MS prevalence since 2013 | ≈ 50% | Walton et al., 2020 (MS Journal) |
| Persons living with MS worldwide | ≈ 2.8 million | MSIF Atlas of MS, 3rd Edition (2020) |
| Rapidly progressing ("malignant") MS in Black Americans | 2.6× higher (7.3% vs 2.9%) | Williams et al., 2022 (Neurology) |
| Black Americans in two most severe MS disability tiers | 41.5% (vs 29.3% White) | NY State MS Consortium / Williams et al., 2022 |
| Median MS Severity Score: Black vs White Americans | 6.0 vs 4.8 | NY State MS Consortium |
| African providers citing specialist shortage as MS diagnostic barrier | 44%–66% | AFRICTRIMS Cross-Sectional Survey |
Note. Figures represent the most current peer-reviewed estimates available as of 2025–2026. Where regional medians are reported, individual country values may vary substantially due to ascertainment limitations.
Expert AnalysisWhat the Evidence Tells Us
Data from the Multiple Sclerosis International Federation Atlas of MS, Third Edition confirm that Africa records the lowest median MS prevalence of any WHO region — 0.3 per 100,000 — yet 25 African nations have no national MS data at all. This is absence of data, not absence of disease. Africa's MRI density of 0.7 scanners per million is the lowest in the world, and MS cannot be confirmed without imaging. The combination of vanishingly thin diagnostic infrastructure and chronic undercounting produces a population of people who carry MS without a name for it.
A 2025 prospective study in Zambia documented a median diagnostic delay of 11.4 months from symptom onset to MS diagnosis, with the upper range extending to 35 months. The majority of that delay was attributable to the health system itself — not to patient hesitation. Recent epidemiological work in Sudan, Kenya, and South Africa similarly suggests that MS ascertainment among Black African populations is rising, indicating the long-standing assumption of low African MS prevalence reflected diagnostic invisibility rather than biological absence.
The diaspora picture is equally stark. Black Americans with MS carry a 2.6-fold higher prevalence of rapidly progressing ("malignant") disease than White Americans (7.3% vs 2.9%), with 41.5% sitting in the two most severe Multiple Sclerosis Severity Scale tiers compared with 29.3% of their White counterparts. Median severity scores are 6.0 versus 4.8. These disparities are not explained by genetic ancestry alone — health system access, diagnostic delay, and social determinants of health drive a substantial share of the gap. This makes MS one of the clearest case studies in neurological inequity across both continental Africa and the African diaspora.
ANNI's ResponseHow ANNI Is Responding to the MS Burden
Awareness
Delivers public education that names MS in African and diaspora communities where it has long been culturally invisible. ANNI develops symptom-recognition materials adapted for African languages and faith-based settings, with particular emphasis on the early symptoms — optic neuritis, sensory disturbance, fatigue — most often dismissed or misattributed in primary care.
Screening
Builds referral pathways from primary care and community health workers into the tertiary centres where MRI and neurological evaluation are available. ANNI's screening model is designed to flag the clinical pattern that should trigger MS workup, even where imaging is not on site, reducing the 11-month diagnostic delay documented in Zambia and similar settings across the continent.
Research Hub
Establishes the first African-led MS patient registries to generate prevalence, incidence, and outcome data from the continent itself — directly addressing the 25-nation evidence vacuum identified by the MSIF Atlas. The registry framework is designed for cross-border interoperability with diaspora research networks studying Black MS populations in the United States and United Kingdom.
Capacity Building
Partners with neurology training programmes and continental bodies including AFRICTRIMS to expand the MS knowledge base among African neurologists and primary-care clinicians. The aim is structural: closing the 44–66% specialist-shortage gap documented in cross-sectional surveys of African MS providers, and embedding MS as a recognised condition within neurology residency curricula across the continent.
📚 Resourcesces
All sources cited on this page are available in our Resources Library.